Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmisartan + s-amlodipine + atorvastatin is a fixed-dose combination drug used primarily for the management of patients with both hypertension and dyslipidemia. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, leading to vasodilation. S-amlodipine is the S-enantiomer of amlodipine, a calcium channel blocker (CCB), which relaxes vascular smooth muscle and further reduces blood pressure. Atorvastatin is a statin that inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver and lowering LDL cholesterol levels while modestly increasing HDL cholesterol. This triple combination targets cardiovascular risk factors by simultaneously controlling high blood pressure and abnormal lipid profiles[6][3]. It is indicated for patients who require all three agents to achieve optimal control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + s-amlodipine + atorvastatin.